Achillion Pharmaceuticals Inc.

Achillion shareholders approve $930M Alexion takeover

Shareholders of Achillion Pharmaceuticals have overwhelmingly approved the company’s takeover by fellow New Haven-born drug maker Alexion Pharmaceuticals for $930 million.

IsoPlexis raises $25M to fund expansion

Branford biotech IsoPlexis Corp., which has developed a technology that can help doctors predict how cancer patients...

NH biotechs report 1Q earnings

Several of New Haven’s publicly traded biotechs reported first-quarter financial results recently, with all but one meeting...

🔒Duffy’s roots stretch to Melinta’s founding

Erin Duffy joined Melinta Therapeutics Inc. shortly after its founding, evolving into her current role as chief scientific officer as the company itself evolved from aspiring startup to the cusp of its first antibiotic approval and a pipeline that includes a new class of antibiotics targeting bacterial superbugs.

- Advertisement -

Achillion’s Deshpande saw ’13 pay triple

Milind S. Deshpande, who was promoted to president and CEO of New Haven's Achillion Pharmaceuticals 11 months ago, saw his pay package jump by more than $3 million in 2013, the company disclosed in a public filing.

Achillion slows 3Q cash burn

New Haven development-stage biotech Achillion Pharmaceuticals Inc. said it lost less money in its third quarter, which ended with a bit of bad news from federal regulators about one of its Hepatitis C drug candidates.

Achillion shares plummet after FDA decision

New Haven's Achillion Pharmaceuticals' stock price was down as high as 52 percent in pre-market trading today after a late Friday announcement that the U.S. Food and Drug Administration would keep a clinical hold its Hepatitis C drug candidate sovaprevir.